Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancerFlorian Castet, Teresa Macarulla, Jin Won Kim et al.|Journal of Hepatology|2025Cited by 4
Phase II trial of neoadjuvant mFOLFOX 6 with panitumumab (P) in T3 rectal cancer with clear mesorectal fascia (MRF) and <i>KRAS</i>, <i>NRAS</i>, <i>BRAF</i>, <i>PI3KCA</i> wild type (4WT). GEMCAD 1601 PIER trial.Carlos Fernández-Martos, Carles Pericay, Joan Maurel et al.|Journal of Clinical Oncology|2021Cited by 3